Why the study?
Do PAI-1 and ACE gene polymorphisms affect plasma PAI-1 antigen levels in subjects attending a metabolic ward?
Do PAI-1 and ACE gene polymorphisms affect plasma PAI-1 antigen levels in subjects attending a metabolic ward?
The 4G/5G polymorphism of the PAI-1 gene significantly influences plasma PAI-1 antigen levels, with the association between triglycerides and PAI-1 being genotype-dependent.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications in metabolic care; extends evidence on PAI-1 polymorphism effects but remains hypothesis-generating.
Plasminogen activator inhibitor 1 (PAI-1) is a determinant of vascular events. Subjects in metabolic wards are at high risk for these events. The renin-angiotensin system modulates plasma PAI-1 levels. An insertion (4G)/deletion (5G) polymorphism is involved in the regulation of the circulating levels of PAI-1. We have evaluated the levels of plasma PAI-1 in 208 individuals from our metabolic ward and correlated these levels with the 4G/5G genotype as well as with a genotype (homozygosity for a deletion polymorphism, DD genotype) of the angiotensin-converting enzyme (ACE) gene. Homozygosity for the insertion genotype (5G/5G) was associated with PAI-1 levels lower than those associated with the deletion genotype (4G/4G) (26.2x/:1.6 versus 33.7x/:1.7 ng/mL, P = .036). Plasma PAI-1 levels appeared to depend on the genotype (P = .014) as much as on age (P = .044), t-PA (P = .0001), or triglyceride levels (P = .005). The association between triglycerides and PAI-1 was significant in subjects carrying the 4G/4G and the 4G/5G genotypes (P = .013 and .036, respectively) but not in those with the 5G/5G genotype. When stratified according to PAI-1 and ACE genotypes, individuals homozygous for both deletions (4G/4G-DD genotypes) exhibited higher plasma PAI-1 levels compared with those of individuals without such homozygosities. However, this difference did not reach statistical significance. We conclude that in a group of subjects from a metabolic ward, a 4G/5G polymorphism of the PAI-1 gene exerts effects on plasma PAI-1 antigen levels comparable to those of established determinants. The association between triglycerides and plasma PAI-1 levels is genotype dependent. A trend to a positive interaction between ACE DD and PAI-1 4G/4G in the regulation of circulating plasma PAI-1 levels is present in this setting.
No takes yet. Share an insight, caveat, or question.
Margaglione et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: